FGF21 and metabolic dysfunction-associated steatohepatitis: As mentioned before, FGF21 can improve the development of CVMDs, including atherosclerosis, CAD, MI, H/R injury, HF, T2DM, obesity, and NASH, in vivo and in vitro.